Harvard Bioscience, Inc. (HBIO) is making moves to slim down and speed up. The company announced Friday it's reshaping its manufacturing footprint in a bid to cut costs and streamline production, and investors seemed to like what they heard.
Harvard Bioscience Closes Massachusetts Plant in Push for Leaner Operations
Get Harvard Bioscience Alerts
Weekly insights + SMS alerts
Shuttering Massachusetts, Going National and International
Here's the plan: Harvard Bioscience is closing its Holliston, Massachusetts plant. Domestic manufacturing will consolidate at the company's Minneapolis, Minnesota hub, while some production heads overseas to facilities in Germany, Sweden, and the United Kingdom.
CEO John Duke framed the reorganization as building on flexibility gained from recent refinancing. The idea is to consolidate key operations and leverage scale and expertise that's already sitting across their various sites.
The math here is pretty straightforward. Management projects roughly $3 million in savings during 2027, ramping up to about $4 million in annual savings once everything's fully implemented beginning in 2028. Those gains come from lower overhead, trimming the SKU count, and making better use of existing assets.
Managing the Transition
The company is reconfiguring roles throughout its operations and working through a phased transition plan. Leadership emphasized they're focused on maintaining order fulfillment and product quality while everything shifts around.
The Holliston facility isn't closing overnight—it'll stay operational through 2026 to keep supporting customers. Harvard Bioscience expects to wrap up the entire consolidation by the first quarter of 2027.
Of course, nothing comes free. Transition-related costs will likely push expenses higher into mid-2027.
HBIO Price Action: Shares were up 0.63% at $0.54 during premarket trading on Friday. The stock has dropped over 69% in the past year.
More News

Microsoft and Stellantis Are Building 100 AI Tools for Your Car. Here's What That Means.
Circle April 20th on your calendar

Schwab's Record Quarter Meets Crypto Rollout, But Stock Takes a Dive

PayPal's Rough Ride: Lawsuits, Scrapped Targets, and a Venmo Bright Spot

A Senator's Magnificent Seven Shopping Spree: Why He's Betting on Microsoft and Nvidia in 2026

Trump's Executive Order 14330: What Wall Street Doesn't Want You to Know

Navitas Semiconductor Stock Surges 13% After Adding Broadcom Veteran to Board

TotalEnergies Stock Jumps on Strong First-Quarter Forecast
Get Harvard Bioscience Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all news
Microsoft and Stellantis Are Building 100 AI Tools for Your Car. Here's What That Means.

Trump's Executive Order 14330: What Wall Street Doesn't Want You to Know (Ad)

Schwab's Record Quarter Meets Crypto Rollout, But Stock Takes a Dive

PayPal's Rough Ride: Lawsuits, Scrapped Targets, and a Venmo Bright Spot

A Senator's Magnificent Seven Shopping Spree: Why He's Betting on Microsoft and Nvidia in 2026
Mar-a-Lago Bombshell (Ad)

Navitas Semiconductor Stock Surges 13% After Adding Broadcom Veteran to Board





